Incannex Begins DReAMzz Phase 2 Dosing; Reports About $70 Million in Cash and No Debt
In a corporate update furnished under Item 7.01, Incannex said patient dosing has started in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, and that a U.S. composition and methods patent covering IHL-42X was granted with a baseline expiry in 2040. The company reported approximately $70 million in cash and no debt as of August 31, 2026. The filing contains no financial results or guidance, so the update covers clinical progress, intellectual property and capital position.
Key points
- DReAMzz study runs at 13 clinical trial sites in the United States; dosing was first announced on August 25, 2026.
- U.S. Patent and Trademark Office granted a patent on June 25, 2026, with a baseline expiry of July 9, 2040.
- Cash of approximately $70 million and no debt as of August 31, 2026; more than A$11.2 million in non-dilutive tax incentive refunds received during 2026.
- PSX-001 for generalized anxiety disorder has an open U.S. IND for a Phase 2b study (PsiGAD2) and a scientific advice meeting with the UK MHRA.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.